No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HOLX Hologic
- 78.110
- +0.450+0.58%
Close Jul 19 16:00 ET
- 77.500
- -0.610-0.78%
Pre 04:15 ET
18.23BMarket Cap40.26P/E (TTM)
78.590High77.475Low1.66MVolume78.200Open77.660Pre Close129.60MTurnover0.72%Turnover Ratio42.68P/E (Static)233.38MShares81.00052wk High3.76P/B17.98BFloat Cap64.02052wk Low--Dividend TTM230.14MShs Float87.880Historical High--Div YieldTTM1.44%Amplitude0.750Historical Low78.047Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings
Express News | Hologic Inc : Leerink Partners Raises Target Price to $95 From $90
Hologic's Q3 2024 Earnings: What to Expect
Pre Q3 Earnings: Is Hologic (HOLX) Stock a Portfolio Must-Have?
Hologic (HOLX) Exceeds Market Returns: Some Facts to Consider
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
Comments
$Hologic(HOLX.US$ Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography 3 MINUTES AGO, 2:07 PM EDT VIA BUSINESSWIRE Collaboration Includes Robust Education and Training to Support Radiologists and Imaging Specialists Bayer and Hologic, Inc. (NASDAQ:HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two ...
1
Multiple insiders selling shares could be a red flag. The absence of insider purchases and significant selling over the last three months may suggest insiders believe the shares are overpriced. Despite high insider ownership, the lack of buying and significant selling raises concerns about the company.
Undervalued Hologic presents opportunity to accumulate stocks. Investors cautioned to consider financial health. Company's outlook suggests further growth not reflected in share price.
I've been eyeing the news on this sector and it finally gained some traction. I agree Dare is another good one
Gapping up
$Visa(V.US$ +1.1%, $MasterCard(MA.US$ +1.7% (Keybanc upgraded their ratings to overweight from from sector weight.)
$Zillow-C(Z.US$ +4% (Bank of America double upgraded the stock to buy, citing its improved growth outlook despite a challenging macroeconomic environment.)
$Hologic(HOLX.US$ +2.8% (The women's diagnostics provider reported fiscal first quarter revenue Sunday that topped its most recent guidance and Wall Str...
$Visa(V.US$ +1.1%, $MasterCard(MA.US$ +1.7% (Keybanc upgraded their ratings to overweight from from sector weight.)
$Zillow-C(Z.US$ +4% (Bank of America double upgraded the stock to buy, citing its improved growth outlook despite a challenging macroeconomic environment.)
$Hologic(HOLX.US$ +2.8% (The women's diagnostics provider reported fiscal first quarter revenue Sunday that topped its most recent guidance and Wall Str...
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg